Walleye Trading LLC Immuno Gen, Inc. Put Options Transaction History

Walleye Trading LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $347,634 - $835,605	27,900 Added 226.83%	40,200 $1.19 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $87,358 - $123,194	6,200 Added 101.64%	12,300 $195,000
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $22,875 - $122,305	6,100 New	6,100 $115,000
Q2 2022 Aug 08, 2022	SELL	$3.15 - $5.76 $3,780 - $6,912	-1,200 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.26 - $7.48 $5,112 - $8,976	-1,200 Reduced 50.0%	1,200 $6,000
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $11,400 - $18,000	2,400 New	2,400 $18,000
Q1 2019 May 15, 2019	SELL	$2.41 - $5.91 $5,543 - $13,593	-2,300 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.94 - $9.7 $4,728 - $11,640	1,200 Added 109.09%	2,300 $11,000
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $9,460 - $12,386	1,100 New	1,100 $10,000
Q2 2018 Aug 14, 2018	SELL	$9.52 - $12.15 $373,184 - $476,280	-39,200 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$6.7 - $12.95 $262,640 - $507,640	39,200 New	39,200 $412,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Trading LLC with notifications on news.